Cryoport Inc
$ 9.88
4.99%
04 Dec - close price
- Market Cap 494,681,000 USD
- Current Price $ 9.88
- High / Low $ 9.90 / 9.08
- Stock P/E N/A
- Book Value 9.45
- EPS -1.22
- Next Earning Report 2026-03-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.11 %
- 52 Week High 11.44
- 52 Week Low 4.58
About
Cryoport, Inc. (CYRX) is a leading provider of specialized temperature-controlled logistics solutions for the biopharmaceutical and life sciences sectors, headquartered in Brentwood, Tennessee. The company offers a robust suite of global supply chain management services designed to ensure the integrity and regulatory compliance of sensitive biological products across diverse markets, including the Americas, Europe, the Middle East, Africa, and Asia Pacific. With its advanced logistics technology and unwavering commitment to quality, Cryoport is instrumental in facilitating the delivery of critical therapies, establishing itself as a strategic partner in the dynamic healthcare ecosystem.
Analyst Target Price
$13.22
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-12 | 2025-05-05 | 2025-03-10 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-08 | 2023-08-09 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.18 | -0.28 | -0.3836 | -0.4271 | -0.02 | -0.29 | -0.43 | -1.31 | -0.31 | -0.42 | -0.16 | -0.24 |
| Estimated EPS | -0.24 | -0.27 | -0.2577 | -0.3064 | -0.29 | -0.39 | -0.35 | -0.29 | -0.3 | -0.24 | -0.19 | -0.19 |
| Surprise | 0.06 | -0.01 | -0.1259 | -0.1207 | 0.27 | 0.1 | -0.08 | -1.02 | -0.01 | -0.18 | 0.03 | -0.05 |
| Surprise Percentage | 25% | -3.7037% | -48.8553% | -39.393% | 93.1034% | 25.641% | -22.8571% | -351.7241% | -3.3333% | -75% | 15.7895% | -26.3158% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2105 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYRX
2025-11-01 00:06:00
Cryoport Inc (CYRX) is expected to report a loss of 21 cents per share on November 4 for the quarter ending September 30, 2025, with an anticipated 27.0% decrease in revenue. Analysts currently rate the shares as "buy," with a median 12-month price target of $13.00. The company's past quarterly performance has shown a mix of beats and misses on earnings estimates.
2025-10-30 08:30:00
Cryoport, Inc. announced that its subsidiary, Cryoport Systems, has achieved ISO 21973:2020 certification for the transportation of human cells for therapeutic use. This makes Cryoport the first global supply chain solutions company to earn this certification, reinforcing its leadership in ensuring the highest safety, traceability, and integrity standards for cell and gene therapies. The certification highlights Cryoport's commitment to critical conditions monitoring and risk minimization in regenerative medicine supply chains, extending these standards across its life sciences operations.
2025-10-19 12:09:10
Cryoport (CYRX) has introduced new monitoring technology for its life sciences logistics solutions, leading to a recent surge in its stock price. Despite recent gains, the company's long-term shareholder returns remain negative. The article assesses Cryoport's valuation, suggesting it is undervalued based on the accelerating adoption of cell and gene therapies and the potential for significant earnings turnaround.
2025-10-18 11:15:15
Cryoport (CYRX) has upgraded its MVE Biological Solutions with new integrated smart monitoring for its cryogenic dewars, enhancing data management for critical temperature-sensitive materials. This innovation addresses growing demands for safety and compliance in life sciences logistics but does not immediately reduce Cryoport's revenue concentration risk on a few commercial therapy clients. Despite these technological advancements, the company's financial performance remains heavily dependent on the sustained commercialization success of cell and gene therapies.
2025-10-17 20:43:05
CryoPort, Inc. (NASDAQ:CYRX) recently achieved a new 52-week high of $11.34 amidst robust trading, following positive analyst ratings that raised target prices to $15.00 and $16.00. Despite a director's sale of shares reducing their ownership by 32.78%, institutional investment in CYRX has seen significant increases, with 92.90% of the stock now owned by institutional investors. The company's financial performance includes a market cap of $536.25 million and a P/E ratio of 8.05, though it missed Q2 EPS estimates while exceeding revenue expectations.
2025-10-15 18:30:51
CryoPort (NASDAQ:CYRX) saw its stock price increase by 9.1% to $10.17, despite a significant drop in trading volume. Analysts have issued "Moderate Buy" ratings with price targets between $13.00 and $16.00. The company reported revenue of $45.45 million, exceeding expectations, but missed EPS estimates with a net loss of ($0.29).
